Drug
Trientine
Trientine is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_1
1
25%
Ph phase_2
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
NCT04706429
completed
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients
NCT03299829
completedphase_1
Trientine and Carboplatin in Advanced Malignancies
NCT01178112
completedphase_3
Study of Tetrathiomolybdate in Patients With Wilson Disease
NCT00004339
Clinical Trials (4)
Showing 4 of 4 trials
NCT04706429Phase 2
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
NCT03299829
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients
NCT01178112Phase 1
Trientine and Carboplatin in Advanced Malignancies
NCT00004339Phase 3
Study of Tetrathiomolybdate in Patients With Wilson Disease
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4